“KBB (Knowledge Beyond Borders) is an Hetero Biopharma Initiative!
This initiative has been designed to spread the awareness on Biologics & Biosimilars to win the acceptance of regulators, policy makers, prescribers and patients across the globe.
To further our mission of REACHing every needy patient across the world, KBB will act as a dedicated Biosimilars knowledge exchange platform for various stake holders to increase the access of Biosimilars.
KBB - First of its kind initiative by a Biosimilar company in Emerging markets
Need of KBB
Partners, Prescribers & Patients across emerging markets lack a clear understanding of Biologics, Biosimilars and the applications of them in ever challenging situations of addressing the chronic ailments like Oncological, Rheumatological, Nephrological disorders.
Real time challenges faced by them are:
- Awareness on need of Biologics in the treatment of chronic diseases & disorders
- Lack of understanding on challenges in development, manufacturing, testing and approvals of Biosimilars.
- Wrong perception on Biosimilars created by Innovators to block the entry.
- Safety, efficacy, Interchangeability & Immunogenicity concerns.
- Understanding of pharmacoeconomics.
Our Approach
To build a “Knowledge centric medico marketing ecosystem” by conducting continuous medical, clinical, regulatory and marketing education on Biosimilars to various stake holders across the globe.
Below are the activities:
- Skill upgradation programs involving top KOL’s around the world
- Debate & panel discussions on case & user studies from different parts of the world
- Publication of clinical outcomes of our studies
- Patient support groups
- Effectively use social media to maximize our influence on society
- Concept clinics dedicated to address specific ailments
- Rheumatology clinics
- Anemia clinics
KBB: List of activities
| S.no | Date | Topic | Name of the Speaker | No.of Participants Engaged | No.of Countries | Asia / CIS | Africa |
|---|---|---|---|---|---|---|---|
| 1 | 30-04-2020 | Shooting in the Dark in Metastatic Solid Tumor | Dr. Suresh VS Attili, MD DM Medical Oncologist and Hematologist | 81 | 13 | Cambodia, Myanmar, srilanka, uzbekistan,Georgia | Kenya,Uganda,Zambia,Zimbabwe,Nigeria, Tanzania, IVC, Rwanda |
| 2 | 02-05-2020 | Be Specific in B-Cell Tumors | Dr. Suresh VS Attili, MD DM Medical Oncologist and Hematologist | 82 | 13 | Cambodia, Myanmar, srilanka, uzbekistan,Georgia | Kenya,Uganda,Zambia,Zimbabwe,Nigeria, Tanzania, IVC, Rwanda |
| 3 | 11-05-2020 | AIDA Model Hirearchy | Mr.Shanker Maharaju | 30 | 5 | Myanmar | Nigeria,kenya, zimbabwe,Tanzania, IVC,Uganda |
| 4 | 12-05-2020 | Managing CKD anemia patients during Covid -19 Pandemic | Dr.Dharshan R, MD DM ISN Scholar(Multiorgan Transplant) | 105 | 14 | Cambodia, Bangladesh Myanmar, srilanka, uzbekistan,Georgia | Kenya,Uganda,Zambia,Zimbabwe,Nigeria, Tanzania, IVC, Rwanda |
| 5 | 13-05-2020 | Rapid for Inclinic Effectiveness | Mr. Sharath D | 48 | 11 | Srilanka, Bangladesh,Myanmar, Cambodia | Kenya,Uganda,Zambia ,Zimbabwe,Nigeria, Tanzania, IVC, |
| 6 | 14-05-2020 | Effective Forecasting | Mr.T Sai Pavan | 59 | 12 | Srilanka, Bangladesh,Myanmar, Cambodia,Georgia | Kenya,Uganda,Zambia ,Zimbabwe,Nigeria, Tanzania, IVC, |
| 7 | 15-05-2020 | Customer Relation Management - A sales personnal perspective | Mr. Ramesh Reddy y | 74 | 13 | Srilanka, Bangladesh,Myanmar, Cambodia,Uzbekistan | Kenya,Uganda,Zambia ,Zimbabwe,Nigeria, Tanzania, IVC,Angola |
| 8 | 16-05-2020 | Art of Objection Handling - Pharmaceutical Sales | Mr.Vinod A | 72 | 14 | Srilanka, Bangladesh,Myanmar,Cambodia,Uzbekistan,Georgia | Kenya,Uganda,Zambia ,Zimbabwe,Nigeria, Tanzania, IVC,Angola |
| 9 | 18-05-2020 | The Power of organization Purpose and It's Impacton Business Objectives | Mr.Krishna kishore | 53 | 13 | Srilanka, Bangladesh,Myanmar,Cambodia,Uzbekistan | Kenya,Uganda,Zambia ,Zimbabwe,Nigeria, Tanzania, IVC,Angola |
| 10 | 19-05-2020 | HOW TO BRIDGE (Build Relationships by Involving, Developing, and Growing Engagements ) |
Dr. Vikram Kumar shetty | 30 | 9 | Bangladesh, cambodia | kenya,Nigeria,Uganda Zimbabwe,Nigeria, Angola,Tanzania,IVC |
| 11 | 23-05-2020 | Managing Complications during Dialysis & Cost Effective Dialysis | Mr.Lakshmi Pathy | 105 | 12 | Russia,Myanmar,Srilanka, Singapore | Kenya,Nigeria,Uganda, Zimbabwe,Tanzania,IVC,South Africa,Mauirtius |
| 12 | 06-06-2020 | I. Dialysis- Are we doing in rightway? II. Managing CKD anemia- Is It Important? |
Dr.Vikram Kumar Shetty Mr.Lakshmi pathy |
98 | 10 | Myanmar,cambodia,srilanka ,Bangladesh | Kenya,Uganda,Tanzania ,Zimbabwe,Ivoary coast,NIGERIA |
| 13 | 17-06-2020 | Biosimilars - Value addition to your Business | Dr.AV Jayapla Reddy | 93 | 75 | Myanmar,Srilanka,Bangladesh,Cambodia, Uzbekistan,Nepal, Georgia,Krygstan | Kenya,Nigeria,Uganda,Rwanda,Mali,Ghana Zimbabwe,Tanzania,IVC,South Africa,Mauirtius |
| 14 | 03-07-2020 | Role of Biologics in Rheumatoid Arthritis & Rituximab use in Rheumatology- The Nigerian Experience | Dr.Sarvajeet Pal & Prof Olufemi Oladipo Adelowo | 95 | 13 | Myanmar,cambodia,srilanka ,Bangladesh | kenya,Nigeria,Uganda Zimbabwe,Nigeria, Angola,Tanzania,IVC& Rwanda |
